Why the study?
Does ICD therapy prevent sudden death and improve overall survival compared to d,l-sotalol in patients with coronary artery disease and sustained VT/VF?
Does ICD therapy prevent sudden death and improve overall survival compared to d,l-sotalol in patients with coronary artery disease and sustained VT/VF?
ICD therapy is significantly more effective than electrophysiologically guided antiarrhythmic treatment with d,l-sotalol in preventing sudden death and reducing total mortality in patients with coronary artery disease and sustained VT/VF.
Answers are grounded in this paper and cite their sources.
ICD may reduce sudden death and mortality versus sotalol in CAD with VT/VF; hypothesis-generating and requires randomized confirmation.
BACKGROUND: Implantable cardioverter-defibrillators (ICDs) and d,l-sotalol are widely used to treat ventricular tachyarrhythmia and ventricular fibrillation (VT/VF). The purpose of this study was to compare the long-term efficacy of d,l-sotalol and ICDs in patients with coronary artery disease. METHODS AND RESULTS: In a case-control study, 50 patients treated with oral d,l-sotalol were matched to 50 patients treated with ICDs. Both groups were matched for sex (82 men), age (58 +/- 10 years), ejection fraction (40 +/- 12%), extent of coronary artery disease, presenting arrhythmia, and year that treatment began. In all patients in the sotalol group, VT/VF was inducible in the drug-free electrophysiological study. Induction of sustained VT/VF was suppressed by d,l-sotalol (438 +/- 95 mg/d). In the ICD group, either VT/VF was not inducible (n = 5) or inducible sustained VT/VF was refractory to antiarrhythmic drug treatment (n = 45). Sotalol treatment led to a marked reduction in arrhythmic events. Whereas 83% of the patients in the sotalol group were free of sudden death and nonfatal VT at 3 years, only 33% of the ICD patients did not receive appropriate ICD therapies (P < .005). Actuarial rates for absence of sudden death at 3 years were 85% in the sotalol group and 100% in the ICD group (P < .005). Actuarial rates for overall survival at 3 years were 75% in the sotalol group and 85% in the ICD group (P = .02). CONCLUSIONS: In this case-control study, ICD therapy was more effective tha electrophysiologically guided antiar-rhythmic treatment with d,l-sotalol in prevention of sudden death and reduction of total morality in patients with coronary artery disease. Prospective studies are needed to confirm these results.
No takes yet. Share an insight, caveat, or question.
Haverkamp et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: